Key result
Modifying viral MHC class I anchor residues enhances immunity to embedded antigens in recombinant picornavirus vaccines.
Why the study?
Recombinant virus vaccines are often less effective due to immunodominant responses against endogenous vector antigens, limiting immune targeting to desired vaccine antigens.
Modifying immunodominant epitopes in recombinant picornavirus vectors enhances targeted immune responses to vaccine antigens.
Epitope engineering improves immune responses in animal vaccine models; extends vector design options but leaves open human applicability.
Recombinant virus vaccines are often less effective due to immunodominant responses against endogenous vector antigens. However, the use of small RNA virus vectors provides an opportunity to limit host exposure to endogenous virus antigens and focus immune responses on the desired vaccine antigen. Using the Daniel's strain of Theiler's murine encephalomyelitis virus, we have identified strategies to modulate responses to endogenous viral proteins by manipulating the host CD8+ T-cell repertoire prior to infection or through the use of mutations introduced into the virus genome. Both of these approaches enhance responses to vaccine antigens introduced into the picornavirus. However, the use of mutant immunodominant epitopes provides an opportunity for enhancing vaccine responses without further manipulation of the host. Using this strategy, we demonstrate that modification of the consensus MHC class I anchor residue within the virus genome can promote enhanced immunity to foreign antigens and self-antigens embedded in the virus genome.
No takes yet. Share an insight, caveat, or question.
Bell et al. (2014) studied Vaccine immune response. Modification of the consensus MHC class I anchor residue within the virus genome was evaluated on Immunity to foreign antigens and self-antigens embedded in the virus genome. Modification of the consensus MHC class I anchor residue within the virus genome promoted enhanced immunity to foreign antigens and self-antigens embedded in the recombinant picornavirus vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: